# Prospective Evaluation of Xerava Prophylaxis in Hematological Malignancy Patients With Prolonged Neutropenia

> **NCT05537896** · PHASE2 · RECRUITING · sponsor: **West Virginia University** · enrollment: 55 (estimated)

## Conditions studied

- Hematological Malignancy
- Neutropenia

## Interventions

- **DRUG:** Eravacycline

## Key facts

- **NCT ID:** NCT05537896
- **Lead sponsor:** West Virginia University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-19
- **Primary completion:** 2028-02
- **Final completion:** 2028-02
- **Target enrollment:** 55 (ESTIMATED)
- **Last updated:** 2026-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05537896

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05537896, "Prospective Evaluation of Xerava Prophylaxis in Hematological Malignancy Patients With Prolonged Neutropenia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05537896. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*